TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05781711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa-carbidopa
Description: levodopa-carbidopa is the standard therapy used in Parkinson's disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa-carbidopa
Description: levodopa-carbidopa is the standard therapy used in Parkinson's disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin, a biguanide family member commonly used in treatment for type 2 diabetes, appears to increase liver and peripheral tissue sensitivity to insulin as well as reduce hepatic glucose production
Study: NCT05405985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Nemolizumab with Auto-Injector (AI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Nemolizumab with Dual-Chamber Syringe (DCS).
Study: NCT05808764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Participants will receive 0.15 mg/kg risdiplam orally once daily for 28 days.
Study: NCT06232044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Receive PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Receive PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin
Description: Receive IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Belantamab Mafodotin
Description: Receive IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Receive PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Receive PO
Study: NCT05198557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Description: Participants will receive IV inebilizumab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inebilizumab
Description: Participants will receive IV inebilizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive IV placebo matched to inebilizumab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive IV placebo matched to inebilizumab.
Study: NCT05661240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor treating fields（EFE-P100）
Description: Device: Tumor treating fields（EFE-P100） Subjects will use EFE-P100 until disease progression or for a maximum of 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel injection
Description: Drug: Docetaxel injection Subjects will receive Docetaxel injection until disease progression or for a maximum of 24 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel injection
Description: Drug: Docetaxel injection Subjects will receive Docetaxel injection until disease progression or for a maximum of 24 months.
Study: NCT04799197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kicking it with the Gurlz
Description: The intervention is a multicomponent intervention, including a screening, groups, and individual sessions.
Study: NCT04793334

Intervention type: PROCEDURE
Intervention: sleeve gastectomy
Description: routine sleeve gastrectomy

Intervention type: PROCEDURE
Intervention: sleeve gastectomy
Description: routine sleeve gastrectomy
Study: NCT06027450

Intervention type: OTHER
Intervention: NHIg prescription
Description: Analysis of NHIg prescription
Study: NCT06524323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil Injection
Description: The mixture contains 2mL of triamcinolone acetonide injection and 4mL of 5-fluorouracil injection, which is diluted with saline to 10mL.

Intervention type: DRUG
Group type: OTHER
Intervention: Triamcinolone Acetonide
Description: The mixture contains 2mL of triamcinolone acetonide injection which is diluted with saline to 10mL.
Study: NCT05188131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Infusion of Diclofenac Sodium
Description: Intravenous Infusion of Diclofenac Sodium is administered at the dose of 75 mg, diluted in 100 ml of isotonic saline, over 15 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Infusion of Placebo
Description: Intravenous Infusion of Placebo (represented by 100 ml of isotonic saline) is administered over 15 minutes.
Study: NCT06232044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Receive PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT05033639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 6 MG
Description: Melatonin is an endogenously produced indolamine principally synthesized in the pineal gland from serotonin. It is described as a ubiquitous molecule which plays a vital role in the physiologic function of the body. Melatonin, also known as N-acetyl-5-methoxytryptamine which has a a) immunomodulator; b) free radical scavenger; c) prevention of oxidative stress and d) anti-inflammatory7-10.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Breast Milk
Description: Naturally occurring milk from the mother of the infant.
Study: NCT05552352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality assisted information
Description: Patients in the intervention group receive a VR instructional application in the patient's room the day before TAVI implantation and in the operational suite during TAVI implantation the next day. In this application, the patient is guided through different VR parts that repeat the indication, the procedure, the localities and the post-interventional phase of the implantation with the corresponding safety instructions.
Study: NCT05391256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated flying Drone carrying an Automated external defibrillator (AED)
Description: Totally n=6 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over up to 12 months Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.~An interventional package directed to the dispatchers is distributed and consists of an e-learning program, an AED -trainer placed at the dispatch center. Within the dispatcher decision tool - there is information how to inform the caller to retrieve the AED. The HEMS-coordinator reminds the dispatcher during the call on operational information. Monthly information to staff of project progress is provided.
Study: NCT05244551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK061
Description: In the escalation part, patients will receive a single dose of oral ABSK061 on C1D1 only, and then BID dosing for the rest of the days of cycle 1 and in subsequent cycles (28-day cycles). The starting dose is 5 mg BID. In the expansion part, patients will each receive oral ABSK061 at the RDE in repeated 28-day cycles.
Study: NCT04692532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8-hour Time restricted eating
Description: Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie restriction
Description: 25% energy restriction every day
Study: NCT01086943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LT2420
Study: NCT04938011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: progesterone
Description: the transfer of day 6 blastocyst on the 6th day of progesterone supplementation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: progesterone
Description: the transfer of day 6 blastocyst on the 7th day of progesterone supplementation
Study: NCT06506409

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smart-Video Based Game Therapy
Description: The Active Arcade program will be practiced 2 days a week for 8 weeks. Individuals in this group will be given a 1-minute rest break between games. Sessions will be approximately 30 minutes. Selected games focus on balance, coordination and weight transfer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Otago Based Structured Exercise
Description: Exercises will be done 2 days a week for 8 weeks and last approximately 30 minutes. In general, if individuals can perform 2 sets of 10 repetitions at a difficulty level with quality, they can move on to a higher difficulty level. It consists of warm-up, balance and strengthening exercises. It was developed to increase balance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: A training presentation based on the guidelines and individuals' needs will be developed for participants in the control group. The presentation will include an infographic developed with the CANVA program, a test created with Google Forms, and a summary video developed with the Powtoon program. The created presentation will be presented online to individuals in the control group, and the participants will be followed by phone once a week for 8 weeks. The topics of the training will be: What is Osteoporosis, Osteoporosis Prevalence, Findings and Risk Factors, Diagnosis of Osteoporosis, Osteoporosis Prevention and Nutrition, Osteoporosis and Exercise, Preventing Falls.
Study: NCT05540834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: The enzyme tissue plasminogen activator that cleaves plasminogen to form plasmin.
Study: NCT01261182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In School Feeding
Description: The intervention provides meals consisting of 1049 kcals of energy, 32.6 gm protein, and 24.9 gm fat per child per school day and meet at least two thirds of the child's daily vitamin and mineral requirements, including 99 percent of iron requirements. SFP delivers these nutrients in the form of a fortified corn-soy porridge around mid-morning and beans and maize meal or rice at lunch.
Study: NCT04959305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1803-3
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2003
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2004
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2005
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HPP2003-3
Description: Placebo drug. Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HPP2003-3
Description: Placebo drug. Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HPP2003-3
Description: Placebo drug. Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPP2005
Description: Placebo drug. Take it once daily for 8 weeks orally.
Study: NCT05360745

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ARACOMPLEX®
Description: ARACOMPLEX® is an authorized food supplement that contains maca extract, vitamin complexes and ions, and that improves the quality of life of the patient.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo has a composition that makes its weight and organoleptic characteristics are identical to ARACOMPLEX®.
Study: NCT05825560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OFA multimodal analgesia
Description: Multimodal opioid free analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard multimodal analgesia
Description: Standard remifentanil analgesia
Study: NCT05694299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal bridle
Description: Bridle Pro® Nasal Tube Retaining System (Applied Medical Technology Inc., Brecksville, OH, USA)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal patch
Description: Regular adhesive tape for medical use.
Study: NCT05597553

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Premixed MTA
Description: The premixed Bio-ceramic putty during setting become hard and expand slightly providing a superior long-term seal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Premixed MTA
Description: The premixed Bio-ceramic putty during setting become hard and expand slightly providing a superior long-term seal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Powder/liquid MTA
Description: Mineral trioxide aggregate (MTA) is a silicate material that is said to aid in faster bridge formation with fewer tunnel defects, less pulpal inflammation, and the maintenance of pulpal integrity. It is widely used in pediatric dentistry due to its excellent sealing properties.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Powder/liquid MTA
Description: Mineral trioxide aggregate (MTA) is a silicate material that is said to aid in faster bridge formation with fewer tunnel defects, less pulpal inflammation, and the maintenance of pulpal integrity. It is widely used in pediatric dentistry due to its excellent sealing properties.
Study: NCT05804032

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isatuximab
Description: IV isatuximab will be administered weekly in the first cycle (Cycle 1) on days 1, 8, 15, 22, 29, and biweekly on the 2 subsequent cycles at days 1, 15 and 29, at the dose of 10 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: SC isatuximab will be administered on days 1, 8, 15, 22, 29 of cycle 1, and on days 1, 15 and 29 of cycles 2-3, at the dose of 1400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Both arms: 25 mg per os on day 1-14 and d22-35 in induction cycle 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Both arms: 25 mg per os on day 1-14 and d22-35 in induction cycle 1-3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Both arms: 1.3 mg/m\^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Both arms: 1.3 mg/m\^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 20 mg per os on day 1-2, 4-5, 8-9, 11-12, 15; and 22-23, 25-26, 29-30, 32-33 in induction cycles 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg per os on day 1-2, 4-5, 8-9, 11-12, 15; and 22-23, 25-26, 29-30, 32-33 in induction cycles 1-3.
Study: NCT01261182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Take Home Rations
Description: The rations provided in the intervention are equal in size and composition to the food received in the in-school feeding intervention, but are provided to households once per month.
Study: NCT05905731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR-T
Description: Stage-1: Patients will receive three biweekly HBV-TCR T cell infusions at escalating doses, ranging from 1 x 10\^5 cells/kg to 5 x 10\^6 cells/kg bodyweight (by IV infusion). Patients are to remain on existing HBV NUC treatment.~Stage-2: Patients will receive three biweekly HBV-TCR T cell infusions at maximum dose as determined in Stage-1 study. Patients are to remain on existing HBV NUC treatment.
Study: NCT05350319

Intervention type: RADIATION
Intervention: A low-dose CT scan of the shoulder
Description: Briefly, a conventional CT scan will be conducted, with scan images representing a reconstruction of simultaneous scans at two sensors. L-CT images will be derived from single source data (ie the scan data gathered by one of the emitters rather than a reconstruction from both).
Study: NCT06232044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT04707885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocochleography
Description: The use of ECochG monitoring will be employed. This will be conducted intraoperatively during the entire portion of the CI electrode insertion component.~For the purposes of this clinical trial, the stimulus will consist of a 500 Hz tone burst presented at \~105-110 dB SPL. This was chosen due to the time and resource limitations in the operating room. Hence, the surgical team can only utilize a very limited dataset for intraoperative decision making and previous studies have demonstrated that 500 Hz stimulation offers the most robust, reliable, and useful ECochG signal during electrode insertions.
Study: NCT06232044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05510674

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OWL-EVO1
Description: EVOC probe
Study: NCT04685525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mycobiome Supporting Diet
Description: MSD takes combines elements from several diets (e.g., Paleo, low-carbohydrate, vegetarian, and Mediterranean) and excludes elements of these diets that have been specifically proven to increase pathogenic fungi in the human gut.
Study: NCT05192655

Intervention type: OTHER
Intervention: Observation
Description: Observation Study

Intervention type: OTHER
Intervention: Observation
Description: Observation Study
Study: NCT06284226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic NK（CCT-ANK-11)
Description: allogeneic natural killer cells
Study: NCT05935007

Intervention type: DEVICE
Intervention: Aveir DR Leadless Pacemaker System
Description: This study will utilize real-world data from patients implanted with the Aveir DR Leadless Pacemaker System. No device intervention will be conducted in this study.
Study: NCT04874974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive and Defusion Training
Description: Module I will give a brief introduction into the rational of the therapy and explain the terms cognitive biases and relational responding and their role in the development of psychological problems (psychosis) in a simple language and with the help of examples and small exercises. The principle of metacognition and cognitive defusion in psychotherapy will be made clear. An outlook on the procedures and the goals of the group therapy will be given. Module II will include interventions adapted from the MCT manual (Moritz et al., 2017) and Module III with consist of defusion strategies taken from the ACT group manual (Dambacher et al., 2020) and existing studies on ACT and psychosis (Bach et al., 2013; Gaudiano \& Herbert, 2006).
Study: NCT06460064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fH1 2 ug
Description: 2 administrations at 3-week intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fH1 2 ug
Description: 2 administrations at 3-week intervals.
Study: NCT06232044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study: NCT06460064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fH1 2 ug
Description: 2 administrations at 3-week intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fH1 2 ug
Description: 2 administrations at 3-week intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fH1 8 ug
Description: 2 administrations at 3-week intervals.
Study: NCT06232044

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo Bone Marrow Biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo Bone Marrow Biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo Bone Marrow Biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo Bone Marrow Aspirate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo Bone Marrow Aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo Bone Marrow Aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection